Role of carbohydrate on angiostatin in the treatment of cancer

Journal of Laboratory and Clinical Medicine

Volumn 134, Issue 6, 1999, Pages 553-560

  Pirie Shepherd, Steven R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033486268     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(99)90093-8     Document Type: Article

References (44)

1. 1. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;9:15-28.
2. 2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. 3. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
4. 4. Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
5. 5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86: 353-64.
6. 6. O'Reilly MS, Rosenthal R, Sage EH, Smith S, Holmgren L, Moses M, et al. The suppression of tumour metastases by a primary tumour. Surg Forum 1993;44:474-6.
7. 7. Clark WH Jr, Elder DE, Guerry D IV, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
8. 8. Sottrup-Jensen L, Claeys H, Zajdel M, Petersen T, Magnusson S. The primary structure of human plasminogen: isolation of two lysine binding fragments, and one "mini"- plasminogen (MW 38,000) by elastase catalysed specific limited proteolysis. In: JF Davidson, RM Rowan, MM Samama, PC Desnoyers, editors. Prog chemical fibrinolysis and thrombolysis. New York: Raven Press; 1978. p. 191-209.
9. 9. Castellino J, McCance SG. The kringle domains of human plasminogen. Ciba Found Symp 1997;212:46-65.
10. 10. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997;272: 28823-5.
11. 11. Hayes M. Castellino FJ. Carbohydrate of the human plasminogen variants. III. Structure of the O-glycosidically linked oligosaccharide unit. J Biol Chem 1979;254:8777-80.
12. 12. Hayes M, Castellino FJ. Carbohydrate of the human plasminogen variants. II. Structure of the asparagine-linked oligosaccharide unit. J Biol Chem 1979;254:8772-6.
13. 13. Brockway WJ, Castellino FJ. Measurement of the binding of antifibrinolytic amino acids to various plasminogens. Arch Biochem Biophys 1972;151:194-9.
14. 14. Pirie-Shepherd SR, Stevens RD, Andon NL, Enghild JJ, Pizzo SV. Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2. J Biol Chem 1997;272:7408-11.
15. 15. Dwek RA. Glycobiology: "towards understanding the function of sugars." Biochem Soc Transact 1995;23:1-25.
16. 16. Gonzales-Gronow M, Grennet HE, Fuller GM, Pizzo SV. The role of carbohydrate in the function of human plasminogen: comparison of the protein obtained from molecular cloning and expression in Escherichia coli and COS cells. Biochim Biophys Acta 1990;1039:269-76.
17. 17. Gonzalez-Gronow M, Edelberg JM, Pizzo SV. Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site. Biochemistry 1989;28:2374-7.
18. 18. Hall SW, Vandenberg SR, Gonias SL. Plasminogen carbohydrate side chains in receptor binding and enzyme activation: a study of C6 glioma cells and primary cultures of rat hepatocytes. J Cell Biochem 1990;43:213-27
19. 19. Mori K, Dwek RA, Downing AK, Opdenakker G, Rudd PM. The activation of type 1 and type 2 plasminogen by type I and type II tissue plasminogen activator. J Biol Chem 1995; 270:3261-7.
20. 20. Davidson DJ, Castellino FJ. The influence of the nature of the asparagine 289-linked oligosaccharide on the activation by urokinase and lysine binding properties of natural and recombinant human plasminogens. J Clin Invest 1993;92: 249-54.
21. 21. Pirie-Shepherd SR, Jett EA, Andon NL, Pizzo SV. Sialic acid content of plasminogen 2 glycoforms as a regulator of fibrinolytic activity. Isolation, carbohydrate analysis, and kinetic characterization of six glycoforms of plasminogen. J Biol Chem 1995;270:5877-81.
22. 22. Edelberg JM, Enghild JJ, Pizzo SV, Gonzalez-Gronow M. Neonatal plasminogen displays altered cell surface binding and activation kinetics. Correlation with increased glycosylation of the protein. J Clin Invest 1990;86:107-12.
23. 23. Gonzalez-Gronow M, Weber T, Shearin TV, Gawdi G, Pirie-Shepherd SR, Pizzo SV. Plasmin(ogen) carbohydrate chains mediate binding to dipeptidyl peptidase IV (cd26) in rheumatoid arthritis human synovial fibroblasts. Fibrinolysis and Proteolysis 1998;12:366-74.
24. 24. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92:4730-41.
25. 25. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 1999;96: 2811-6.
26. 26. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci 1997;94:10868-72.
27. 27. Ji WR, Castellino FJ, Chang Y, Deford ME, Gray H, Villarreal X, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998;12:1731-8.
28. 28. Lannutti BJ, Gately ST, Quevedo ME, Soff GA, Paller AS. Human angiostatin inhibits murine hemangioendothelioma tumor growth in vivo. Cancer Res 1997;57:5277-80.
29. 29. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-91.
30. 30. Jenkins N, Parekh RB, James DC. Getting glycosylation right: implications for the biotechnology industry. Nat Biotechnol 1996;14:975-81.
31. 31. Cumming DA. Glycosylation of recombinant protein therapeutics: control and functional implications. Glycobiology 1991;1:115-30.
32. 32. Tanner W, Lehle L. Protein glycosylation in yeast. Biochim Biophys Acta 1987;906:81-9.
33. 33. Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997;57:1329-34.
34. 34. Duman JG, Miele RG, Liang H, Grella DK, Sim KL, Castellino FJ, et al. Mannosylation of Pichia pastoris cellular and recombinant proteins. Biotechnol Appl Biochem 1998;28:39-45.
35. 35. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumours in mice. Nat Med 1996;2:689-92.
36. 36. Davidson DJ, Castellino FJ. Asparagine-linked oligosaccharide processing in lepidopteran insect cells. Temporal dependence of the nature of the oligosaccharides assembled on asparagine-289 of recombinant human plasminogen produced in baculovirus vector infected Spodoptera frugiperda (IPLB-SF-21AE) cells. Biochemistry 1991; 30:6165-74.
37. 37. Davidson DJ, Castellino FJ. Structures of the asparagine-289-linked oligosaccharides assembled on recombinant human plasminogen expressed in a Mamestra brassicae cell line (IZD-MBO503). Biochemistry 1991;30:6689-96.
38. 38. Wu Z, O'Reilly MS, Folkman J, Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 1997;236:651-4.
39. 39. Davidson DJ, Castellino FJ. Oligosaccharide structures present on asparagine-289 of recombinant human plasminogen expressed in a Chinese hamster ovary cell line. Biochemistry 1991;30:625-33.
40. 40. Nguyen JT, Wu P, Clouse ME, Hlatky L, Terwilliger EF. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy. Cancer Res 1998;58: 5673-7.
41. 41. Aoyagi Y, Suzuki Y, Igarashi K, Saitoh A, Oguro M, Yokota T, et al. Carbohydrate structures of human alpha-fetoprotein of patients with hepatocellular carcinoma: presence of fucosylated and non-fucosylated triantennary glycans. Br J Cancer 1993;67:486-92.
42. 42. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998;58:3362-9.
43. 43. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, et al. Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 1998;95:6367-72.
44. 44. Gibbons A. Which of our genes makes us human? Science 1998;281:1432-4.